A clinical trial no longer has to happen entirely inside a research center. Under the FDA's September 2024 final guidance, "Conducting Clinical Trials With Decentralized Elements," a study can hold visits by telehealth, send a participant to a nearby lab for a blood draw, collect readings from a home sensor, or dispatch trial staff to someone's living room. The catch is straightforward: none of that is allowed to soften the safety or the quality of the evidence. As the guidance and its Federal Register notice put it, the regulatory requirements are the same whether or not a trial uses decentralized elements.
Key points#
- The guidance permits telehealth visits, tasks by local providers and labs, home visits by trial staff, and remote data capture by digital devices.
- It deliberately drops the idea of a separate "decentralized trial" and treats decentralization as a set of design choices added to an ordinary study.
- The same safety, oversight, and data-integrity rules apply, with no exceptions carved out for convenience.
- Congress ordered the guidance through section 3606 of the Food and Drug Omnibus Reform Act (FDORA).
- The core judgment is per-task: does moving this specific activity off-site preserve rigor, or not.
A category that became a spectrum#
The most revealing thing about the final guidance is its title. The 2023 draft was called "Decentralized Clinical Trials for Drugs, Biological Products, and Devices," language that implied a distinct kind of study, a DCT, with its own identity. The final version, issued September 18, 2024, speaks instead of trials "with decentralized elements." That is not cosmetic. The FDA is signaling that decentralization is a dial, not a switch. A conventional trial might move one assessment to telehealth and keep everything else on site; another might run almost entirely from participants' homes. Both sit on the same spectrum, and both answer to the same regulations.
This framing also explains why the document reads less like a rulebook and more like a set of design principles. It does not hand you a decentralized template. It hands you a way to reason about each activity in a protocol and decide where that activity belongs.
Why Congress asked for it#
The guidance was not a spontaneous agency initiative. Section 3606(a) of the Consolidated Appropriations Act, 2023, part of FDORA, directed the FDA to clarify how decentralized approaches can support drug and device development. The agency published a draft in May 2023, took public comment, and finalized it the following September. A companion document on digital tools, discussed below, answers the piece of the mandate in section 3606(b).
For chronic-disease research, the appeal is easy to see. Studies in areas like type 1 diabetes and childhood obesity, fields central to a good deal of epidemiologic work, often run for months or years, enroll large and geographically scattered groups, and rely on repeated measurements of things like glucose, weight, or growth. A family in a rural county can take part without a weekly drive to an academic center. The same reach that broadens participation, though, stretches a trial across many hands and places, and managing that spread is exactly what the guidance is built for.
What the guidance permits#
The document endorses a menu of decentralized elements, each with a rationale:
- Telehealth visits can stand in for in-person ones when a task does not need a physical exam or an on-site procedure.
- Local healthcare providers and local laboratories, not otherwise part of the trial, can carry out routine, widely performed tasks such as a standard blood draw or an imaging study close to where a participant lives.
- Home visits by trial personnel can move certain activities to the participant's residence.
- Digital health technologies, including wearables and connected devices, can gather data remotely in the stretches between visits.
Two principles hold the menu together. First, match the task to the setting and the skill it demands: an assessment that anchors a study's primary endpoint belongs with trained trial staff, while a routine procedure can reasonably be handled locally. Second, treat variability as the adversary. Protocols are expected to spell out precisely how each decentralized activity is performed, so that a reading taken in one participant's kitchen can be compared with one taken in another's, or at the central site.
The lines it will not let sponsors cross#
If the permissions are one half of the guidance, the safeguards are the other, and they concentrate on three ways distance can degrade a trial.
Oversight has to travel with the activity. The investigator stays responsible for the conduct of the trial no matter where its pieces happen. The guidance explains how a local provider can perform a specified routine task without being enrolled as a formal sub-investigator, as long as that provider is delivering standard clinical care rather than making trial-specific judgments. A record of who did what, and where, keeps accountability traceable. Sponsors carry a coordination duty on top of that: the scattered activities have to fit together, and data arriving from many sources has to reconcile.
Data has to stay trustworthy. When participants do tasks themselves, such as a self-administered test at home, the guidance calls for clear instruction, perhaps by telehealth or a short pre-recorded video, so the task is done right. When digital tools ship data in from remote locations, sponsors must confirm those tools are secure and fit for purpose. Here the FDA points to its separate December 2023 guidance, "Digital Health Technologies for Remote Data Acquisition in Clinical Investigations," which supplies the detail on choosing and verifying such devices.
Safety has to reach the participant. A decentralized design cannot leave someone without a clear route to care when something goes wrong. The guidance covers how adverse events are spotted, reported, and managed when visits are remote or local, and how the investigator keeps a line of sight on participant safety. It also handles the practical machinery decentralization adds, including how investigational products are stored and, where suitable, shipped, and how informed consent can be obtained remotely or electronically without eroding a participant's understanding of the study.
How to read it without overreaching#
The frequent misreading is to take the guidance as permission to decentralize everything. It is the opposite. It is a method for deciding, element by element, whether moving an activity off-site preserves the safety and integrity that regulation demands. Some assessments will always belong at a site, and the document's real value is that it forces those trade-offs into the open rather than leaving each sponsor to improvise.
If you appraise evidence for a living, that is the point worth carrying away. Wider access is only worth having if the resulting data can still be trusted. The guidance opens the door further without lowering the threshold, and it asks you to prove, activity by activity, that the two goals were kept in balance.
Sources and further reading
Questions and answers
Does this guidance create a new type of clinical trial?
No. The final version deliberately abandons the idea of a separate "decentralized trial." It treats decentralization as design choices added to an ordinary study, and the same regulations apply across the whole spectrum.
Can any doctor near me run part of a trial?
A local healthcare provider can perform a specified, routine task, such as a standard blood draw, without becoming a formal sub-investigator, provided the work is standard clinical care rather than trial-specific judgment. The investigator remains responsible for oversight, and the trial keeps a record of who did what.
Do remote and home-based trials have weaker safety rules?
No. The guidance holds decentralized elements to the same safety and data-integrity standards as site-based trials, and it specifically addresses how adverse events are identified, reported, and managed when visits happen remotely or locally.